U.S. Patent Office Ruled Oculir Patent Invalid Based on Dr. Marc Abreu's Technology for Diabetes Monitoring --
Brain Tunnelgenix Technologies to Launch First Noninvasive Glucose and Brain Temperature Measurement Device
8/19/2010 9:35:58 AM
HAMDEN, Conn.--(BUSINESS WIRE)--The U.S. Patent and Trademark Office (USPTO) has held that all claims in Oculir’s Patent No. 6,958,039 to be invalid as not patentable based on prior art from a patent disclosure by Yale researcher, Dr. Marc Abreu. The final rejection forced Oculir, Inc. of San Diego, CA, to close down, with an undisclosed sum returned to investors, and has paved the way for Brain Tunnelgenix Technologies Corp. (BTT Corp.) to announce that it will launch the first noninvasive glucose testing and brain temperature measurement device for people with diabetes.
comments powered by